BNT162b2 Vaccine Encoding the SARS-CoV-2 P2 S Protects Transgenic hACE2 Mice against COVID-19

Ji, Rui; Qu, Yajin; Zhu, Hua; Yang, Yumei; Vogel, Annette B.; Şahin, Uğur; Qin, Chuan; Hui, Ai‐Min

doi:10.3390/vaccines9040324

Cited by 15 publications

(13 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Spikes from VOCs are being investigated as second-generation vaccine candidates to tackle the challenges associated with protection against SARS-CoV-2 emerging variants [34][35][36][37] and therefore, studying the immune response to Spike variants in natural infection can provide insight into differential Spike immunogenicity. We show that infection with B.1.1.7 elicits a robust neutralizing antibody response against B.1.1.7, P.1 and WT variants.…”

Section: Discussionmentioning

confidence: 99%

“…To counter such mutations and their attendant antigenic changes, vaccines using the Spike proteins from these variants of concern (VOCs) are under investigation. [34][35][36][37] Whether the variant Spikes will elicit a robust neutralizing response with superior cross-neutralizing activity against parental strains and newly emerging variants has not been extensively studied. 26,38,39 Natural infection provides an important opportunity to compare the neutralizing antibody titres and cross-neutralizing activity generated from individuals exposed to different Spike variants and will give insights into how mutations in Spike impact immunogenicity, thereby informing the design of second generation vaccine candidates based on VOCs.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Antibody longevity and cross-neutralizing activity following SARS-CoV-2 wave 1 and B.1.1.7 infections

Dupont

Snell

Graham

et al. 2021

Preprint

View full text Add to dashboard Cite

As SARS–CoV–2 variants continue to emerge globally, a major challenge for COVID–19 vaccination is the generation of a durable antibody response with cross–neutralizing activity against both current and newly emerging viral variants. Cross–neutralizing activity against major variants of concern (B.1.1.7, P.1 and B.1.351) has been observed following vaccination, albeit at a reduced potency, but whether vaccines based on the Spike glycoprotein of these viral variants will produce a superior cross–neutralizing antibody response has not been fully investigated. Here, we used sera from individuals infected in wave 1 in the UK to study the long-term cross-neutralization up to 10 months post onset of symptoms (POS), as well as sera from individuals infected with the B.1.1.7 variant to compare cross–neutralizing activity profiles. We show that neutralizing antibodies with cross-neutralizing activity can be detected from wave 1 up to 10 months POS. Although neutralization of B.1.1.7 and B.1.351 is lower, the difference in neutralization potency decreases at later timepoints suggesting continued antibody maturation and improved tolerance to Spike mutations. Interestingly, we found that B.1.1.7 infection also generates a cross-neutralizing antibody response, which, although still less potent against B.1.351, can neutralize parental wave 1 virus to a similar degree as B.1.1.7. These findings have implications for the optimization of vaccines that protect against newly emerging viral variants.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Antibody longevity and cross-neutralizing activity following SARS-CoV-2 wave 1 and B.1.1.7 infections

Dupont

Snell

Graham

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…These data suggest that immune response kinetics after mRNA vaccination are more rapid than with three other leading vaccine technologies. Multiple studies have demonstrated that mRNA vaccines elicit strong antibody responses in various mouse models [18][19][20][21], as well as robust germinal center responses [22] that may be associated with neutralizing antibody generation [23]. Although a wealth of information has been gained regarding antibody responses induced by mRNA vaccines at later timepoints, the early and immediate humoral immune kinetics of mRNA vaccines remains unclear.…”

Section: Humoral Immune Kinetics In Mice Immunized With Hiv-1 Env Mrna Vaccinementioning

confidence: 99%

mRNA Vaccines Induce Rapid Antibody Responses in Mice

Gebre

Rauch

Roth

et al. 2021

Preprint

View full text Add to dashboard Cite

ABSTRACTmRNA vaccines can be developed and produced quickly, making them attractive for immediate outbreak responses. Furthermore, clinical trials have demonstrated rapid protection following mRNA vaccination. We sought to investigate how quickly mRNA vaccines elicit antibody responses compared to other vaccine modalities. We first examined immune kinetics of mRNA and DNA vaccines expressing SARS-CoV-2 spike in mice. We observed rapid induction of antigen-specific binding and neutralizing antibodies by day 5 following mRNA, but not DNA, immunization. The mRNA vaccine also induced increased levels of IL-5, IL-6 and MCP-1. We then evaluated immune kinetics of an HIV-1 mRNA vaccine in comparison to DNA, protein, and rhesus adenovirus 52 (RhAd52) vaccines with the same HIV-1 envelope antigen in mice. Induction of envelope-specific antibodies was observed by day 5 following mRNA vaccination, whereas antibodies were detected by day 7-14 following DNA, protein, and RhAd52 vaccination. Eliciting rapid humoral immunity may be an advantageous property of mRNA vaccines for controlling infectious disease outbreaks.IMPORTANCEmRNA vaccines can be developed and produced in record time. Here we demonstrate induction of rapid antibody responses by mRNA vaccines encoding two different viral antigens by day 5 following immunization in mice. The rapid immune kinetics of mRNA vaccines can be an advantageous property that makes them well suited for rapid control of infectious disease outbreaks.

show abstract

“… 41 BNT162b2 is a modRNA vaccine that expresses P2 mutant, prefusion spike glycoprotein (P2 S) (version 9). 42 , 43 …”

Section: Delivery Of Mrna Vaccinesmentioning

confidence: 99%

The Development of mRNA Vaccines for Infectious Diseases: Recent Updates

Nitika¹,

Wei²,

Hui³

2021

IDR

View full text Add to dashboard Cite

mRNA-based technologies have been of interest for the past few years to be used for therapeutics. Several mRNA vaccines for various diseases have been in preclinical and clinical stages. With the outbreak of the COVID-19 pandemic, the emergence of mRNA vaccines has transformed modern science. Recently, two major mRNA vaccines have been developed and approved by global health authorities for administration on the general population for protection against SARS-CoV-2. They have been proven to be successful in conferring protection against the ongoing SARS-CoV-2 and its emerging variants. This will draw attention to various mRNA vaccines against infectious diseases that are in the early stages of clinical trials. mRNA vaccines offer several advantages ranging from rapid design, generation, manufacturing, and administration and have strong potential to be used against various diseases in the future. Here, we summarize the mRNA-based vaccines in development against various infectious diseases.

show abstract

BNT162b2 Vaccine Encoding the SARS-CoV-2 P2 S Protects Transgenic hACE2 Mice against COVID-19

Cited by 15 publications

References 12 publications

Antibody longevity and cross-neutralizing activity following SARS-CoV-2 wave 1 and B.1.1.7 infections

Antibody longevity and cross-neutralizing activity following SARS-CoV-2 wave 1 and B.1.1.7 infections

mRNA Vaccines Induce Rapid Antibody Responses in Mice

The Development of mRNA Vaccines for Infectious Diseases: Recent Updates

Contact Info

Product

Resources

About